The upgrade in the price target by a reputable analyst like Yigal Nochomovitz from Citigroup is a strong positive signal for Krystal Biotech. It suggests confidence in the company's future performance and potential for growth, which is likely to positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.